| Target | TNFSF4 |
|---|
| Application | FA, FC |
|---|
| Clonality | Monoclonal |
|---|
| Conjugate | DyLight® 488 |
|---|
| Isotype | Human IgG1κ |
|---|
| Immunogen | Original antibody raised against Human OX40L |
|---|
| Species Reactivity | Human |
|---|
| Formulation | This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
|---|
| Research Area | Cancer, Immunology |
|---|
| Description/Background | Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune diseases.3 Oxelumab recognizes human OX40L (TNFSF4). OX40L is a member of the tumor necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an optimal T cell response and plays a significant role in determining the amount of memory T-cells remaining after the immune response.1 Therapeutic treatments with antibodies against TNFSF can sometimes result in serious side effects.2 More research is needed to understand the precise molecular mechanism of TNF inhibition. This cost-effective, research-grade Anti-Human OX40L (Oxelumab) utilizes the same variable regions from the therapeutic antibody Oxelumab making it ideal for research projects. |
|---|
| Storage Temperature | This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. |
|---|
| Protocols | FA, FC |
|---|
| Clone Number | R4930 |
|---|
| Concentration | 0.2 mg/ml |
|---|
| Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |
|---|
